GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (OTCPK:LDXHF) » Definitions » Total Debt per Share

LDXHF (Lumos Diagnostics Holdings) Total Debt per Share : $0.01 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Total Debt per Share?

$0.01 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Lumos Diagnostics Holdings's Total Debt Per Share for the quarter that ended in Dec. 2024 was $0.01.

Lumos Diagnostics Holdings Total Debt per Share Historical Data

The historical data trend for Lumos Diagnostics Holdings's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Total Debt per Share Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24
Total Debt per Share
0.03 0.03 0.02

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Debt per Share Get a 7-Day Free Trial 0.02 0.03 0.02 0.02 0.01

Lumos Diagnostics Holdings Total Debt per Share Calculation

Lumos Diagnostics Holdings's Total Debt Per Share for the fiscal year that ended in Jun. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(7.11+0.95)/512.94
=0.02

Lumos Diagnostics Holdings's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(6.76+1.04)/748.52
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (OTCPK:LDXHF) » Definitions » Total Debt per Share
Comparable Companies
ASX:UBI ASX:OSL ASX:HMD ASX:AT1 ASX:EYE ASX:CBL ASX:CSX ASX:ADRDA ASX:UCM ASX:IRX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE
Traded in Other Exchanges
LDX:Australia
Address
2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Website
https://www.lumosdiagnostics.com
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.

Lumos Diagnostics Holdings Headlines

From GuruFocus

Lumos Diagnostics Raises $63M AUD in ASX IPO

By Business Wire Business Wire • 07-08-2021

Dr. Jerome Adams, Former U.S. Surgeon General, Joins Lumos Diagnostics as a Strategic Healthcare Adviser

By Business Wire Business Wire • 09-14-2021

Lumos Diagnostics FY21 Full Year Results

By Business Wire Business Wire • 08-31-2021

Lumos Diagnostics Receives Authorization for CoviDx� SARS-CoV-2 Rapid Antigen Test in Canada

By Business Wire Business Wire • 11-03-2021

Economic Evaluation of Lumos Diagnostics' FebriDx� Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually

By Business Wire Business Wire • 10-06-2021